Evidence map›Paper›PMID 34408991›Full record

ArticleJournal of hepatocellular carcinoma2021

Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis.

Shimaa Kilany, Lmyaa Ata, Asmaa Gomaa, Aliaa Sabry, Ali Nada, El-Sayed Tharwa, Gamal Badra, Ashraf Abogabal, Mohamed Elwaraky, Enas Moaz and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Hepatitis C Elimination in Egypt: Story of Success.Pathogens (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shimaa KilanyHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Lmyaa AtaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Asmaa GomaaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.ORCID 0000-0001-9376-4461
Aliaa SabryHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Ali NadaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
El-Sayed TharwaHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Gamal BadraHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Ashraf AbogabalHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Mohamed ElwarakyRadiology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Enas MoazEpidemiology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Sameera EzzatEpidemiology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Ahmed ElsharawyClinical Pathology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Imam WakedHepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.ORCID 0000-0002-9857-8972
Menoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimExisting data are controversial regarding the incidence of hepatitis C (HCV)-related hepatocellular carcinoma (HCC) following directly acting antiviral (DAA) therapy. This prospective study aimed to assess incidence, and risk factorss of HCC following DAA therapy in patients with HCV-related advanced fibrosis (F3) and cirrhosis (F4).

methodsIncidence of HCC was calculated in 1,630 patients with HCV-related F3 and F4 treated with DAA prospectively followed for up to 43 months in a single tertiary referral center and compared to historical controls. Risk factors of incident HCC were also determined.

resultsThe crude outcome rate was 2.15/100 person-years, significantly lower than a similar historical cohort (5.57/100 person-years). Risk of developing HCC was higher with the presence of cirrhosis (F4 vs F3, AHR 3.59) and treatment failure (vs achieving SVR, AHR 3.37). Presence of decompensated cirrhosis, platelet count <100×10

conclusionIncidence of HCC was significantly lower in patients with HCV-related advanced fibrosis and cirrhosis treated with DAAs than in a historical cohort of untreated patients. Decompensated cirrhosis, baseline AFP ≥10 ng/mL, diabetes, and nonresponse to DAA were independent risk factors of incident HCC.

Indexed as

DAAHCCHCC characteristicsHCC incidenceHCC predictors

Identifiers

PMID34408991
PMCPMC8367200
OpenAlexW3189909163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.